Natixis Advisors L.P. Boosts Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Natixis Advisors L.P. lifted its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 150,825 shares of the medical equipment provider’s stock after acquiring an additional 6,204 shares during the quarter. Natixis Advisors L.P. owned 0.07% of Zimmer Biomet worth $18,355,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Naples Money Management LLC acquired a new position in shares of Zimmer Biomet in the 4th quarter valued at approximately $35,000. Activest Wealth Management boosted its stake in Zimmer Biomet by 410.4% during the 4th quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider’s stock valued at $42,000 after acquiring an additional 275 shares during the last quarter. Peoples Bank KS acquired a new position in Zimmer Biomet during the 3rd quarter worth $48,000. Blue Trust Inc. increased its position in shares of Zimmer Biomet by 48.4% in the 4th quarter. Blue Trust Inc. now owns 469 shares of the medical equipment provider’s stock worth $52,000 after purchasing an additional 153 shares during the last quarter. Finally, Quent Capital LLC lifted its position in shares of Zimmer Biomet by 21.6% during the fourth quarter. Quent Capital LLC now owns 518 shares of the medical equipment provider’s stock worth $63,000 after purchasing an additional 92 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analyst Ratings Changes

ZBH has been the topic of a number of research analyst reports. JPMorgan Chase & Co. increased their target price on Zimmer Biomet from $115.00 to $125.00 and gave the stock a “neutral” rating in a report on Friday, February 9th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $140.00 price objective on shares of Zimmer Biomet in a report on Friday, February 9th. Citigroup increased their target price on shares of Zimmer Biomet from $134.00 to $140.00 and gave the stock a “neutral” rating in a report on Wednesday, April 3rd. Truist Financial decreased their price target on shares of Zimmer Biomet from $137.00 to $130.00 and set a “hold” rating for the company in a report on Friday. Finally, Canaccord Genuity Group reissued a “hold” rating and issued a $130.00 target price on shares of Zimmer Biomet in a report on Friday, February 23rd. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, Zimmer Biomet has an average rating of “Hold” and an average target price of $135.40.

Zimmer Biomet Stock Performance

ZBH stock opened at $121.66 on Monday. The company has a market capitalization of $25.03 billion, a P/E ratio of 26.33, a PEG ratio of 2.23 and a beta of 1.03. The company has a quick ratio of 0.80, a current ratio of 1.66 and a debt-to-equity ratio of 0.38. The company has a 50-day simple moving average of $125.30 and a 200 day simple moving average of $120.21. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $102.00 and a fifty-two week high of $147.50.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.87 by $0.07. The business had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. Zimmer Biomet had a net margin of 12.93% and a return on equity of 12.70%. The business’s revenue was up 3.2% on a year-over-year basis. During the same period last year, the firm posted $1.89 earnings per share. Sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.1 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, April 30th. Investors of record on Friday, March 29th were paid a dividend of $0.24 per share. The ex-dividend date of this dividend was Wednesday, March 27th. This represents a $0.96 annualized dividend and a yield of 0.79%. Zimmer Biomet’s dividend payout ratio is currently 20.78%.

Insider Buying and Selling

In other news, VP Chad F. Phipps sold 26,156 shares of the firm’s stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the completion of the transaction, the vice president now owns 44,145 shares in the company, valued at approximately $5,677,929.90. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.70% of the stock is owned by corporate insiders.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.